Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants.

Détails

ID Serval
serval:BIB_33CBAD22AEF4
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants.
Périodique
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Auteur(s)
Noguera-Julian M., Cozzi-Lepri A., Di Giallonardo F., Schuurman R., Däumer M., Aitken S., Ceccherini-Silberstein F., D'Arminio Monforte A., Geretti A.M., Booth C.L., Kaiser R., Michalik C., Jansen K., Masquelier B., Bellecave P., Kouyos R.D., Castro E., Furrer H., Schultze A., Günthard H.F., Brun-Vezinet F., Metzner K.J., Paredes R.
Collaborateur(s)
CHAIN Minority HIV-1 Variants Working group
Contributeur(s)
Paredes R., Metzner K.J., Cozzi-Lepri A., Schuurman R., Brun-Vezinet F., Günthard H., Ceccherini-Silberstein F., Kaiser R., Geretti A.M., Brockmeyer N., Masquelier B.
ISSN
1469-0691 (Electronic)
ISSN-L
1198-743X
Statut éditorial
Publié
Date de publication
02/2016
Peer-reviewed
Oui
Volume
22
Numéro
2
Pages
191-200
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
Plasma drug-resistant minority human immunodeficiency virus type 1 variants (DRMVs) increase the risk of virological failure to first-line non-nucleoside reverse transcriptase inhibitor antiretroviral therapy (ART). The origin of DRMVs in ART-naive patients, however, remains unclear. In a large pan-European case-control study investigating the clinical relevance of pre-existing DRMVs using 454 pyrosequencing, the six most prevalent plasma DRMVs detected corresponded to G-to-A nucleotide mutations (V90I, V106I, V108I, E138K, M184I and M230I). Here, we evaluated if such DRMVs could have emerged from apolipoprotein B mRNA editing enzyme, catalytic polypeptide 3G/F (APOBEC3G/F) activity. Out of 236 ART-naive subjects evaluated, APOBEC3G/F hypermutation signatures were detected in plasma viruses of 14 (5.9%) individuals. Samples with minority E138K, M184I, and M230I mutations, but not those with V90I, V106I or V108I, were significantly associated with APOBEC3G/F activity (Fisher's P < 0.005), defined as the presence of > 0.5% of sample sequences with an APOBEC3G/F signature. Mutations E138K, M184I and M230I co-occurred in the same sequence as APOBEC3G/F signatures in 3/9 (33%), 5/11 (45%) and 4/8 (50%) of samples, respectively; such linkage was not found for V90I, V106I or V108I. In-frame STOP codons were observed in 1.5% of all clonal sequences; 14.8% of them co-occurred with APOBEC3G/F signatures. APOBEC3G/F-associated E138K, M184I and M230I appeared within clonal sequences containing in-frame STOP codons in 2/3 (66%), 5/5 (100%) and 4/4 (100%) of the samples. In a re-analysis of the parent case control study, the presence of APOBEC3G/F signatures was not associated with virological failure. In conclusion, the contribution of APOBEC3G/F editing to the development of DRMVs is very limited and does not affect the efficacy of non-nucleoside reverse transcriptase inhibitor ART.

Mots-clé
Antiretroviral Therapy, Highly Active, Case-Control Studies, Cytidine Deaminase/genetics, Cytosine Deaminase/genetics, Drug Resistance, Viral, Female, HIV Infections/drug therapy, HIV Infections/metabolism, HIV Infections/virology, HIV-1/genetics, Humans, Male, Mutation, RNA Editing, RNA, Viral/genetics, RNA, Viral/metabolism, Reverse Transcriptase Inhibitors/therapeutic use
Pubmed
Open Access
Oui
Création de la notice
05/04/2016 18:15
Dernière modification de la notice
08/05/2019 16:51
Données d'usage